The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation. Chilcott JB, Holmes MW, Walters S, Akehurst RL, Nashan B. Transplant International 2005;15(9/10):486-93.
Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients. Holmes MW, Chilcott J, Walters SJ, Whitby S, Akehurst RL. Transplant International 2004;17(4):182-7.
The clinical and cost-effectiveness of pulsatile machine perfusion vs. cold storage of kidneys for transplantation retrieved from heart beating and non-heart beating donors. Wight J, Chilcott J, Holmes MW, Brewer N. Health Technology Assessment 2003;7(25).
Pulsatile machine perfusion vs. cold storage of kidneys for transplantation: a rapid and systematic review. Wight JP, Chilcott JB, Holmes MW, Brewer N. Clinical Transplantation 2003;17(4):293-307.
Modelling of long-term consequences of the use of basiliximab in renal transplantation. Holmes MW, Chilcott JB, Walters S, Akehurst RL. Nephrology Review 2001;58(2):61-5.
Modelowanie dugotrotrwaych skutków stosowania bailiximabu (SIMULECTU) u chorych po przeszczepieniu nerki w Wielkiej Brytanii. Chilcott J, Holmes M, Walters S, Akehurst RL. Przeglad Lekarski 2001;52(2):61-6.
